The Scientific World Journal / 2012 / Article / Tab 2 / Clinical Study
Polymerized-Type I Collagen Downregulates Inflammation and Improves Clinical Outcomes in Patients with Symptomatic Knee Osteoarthritis Following Arthroscopic Lavage: A Randomized, Double-Blind, and Placebo-Controlled Clinical Trial Table 2 Clinical characteristics of the patients.
Placebo (
𝑛
=
9
) Polymerized-type I collagen (
𝑛
=
1
0
) Baseline 3 months 6 months Baseline 3 months 6 months Patient pain (mm); mean ± SD 7.5 ± 1.2 4.8 ± 3.1 5.5 ± 2.3 7.2 ± 2.3 2.6 ± 2.5 2.7 ± 2.3 Median 8.0 4.0 5.5 8.0 1.7 2.0 Range (6.0–9.0) (1.0–9.0) (1.0–8.5) (4.0–10.0) (0.5–7.8) (0.0–6.5) Physician pain (mm); mean ± SD 7.6 ± 1.5 3.4 ± 3.0 5.1 ± 2.3 7.6 ± 1.8 2.7 ± 2.9 2.8 ± 2.1 Median 8.0 2.0 4.8 8.0 1.9 2.0 Range (5.5–9.0) (1.0–9.1) (1.0–8.0) (4.0–10.0) (0.0–8.0) (0.0–6.0) Lequesne; mean ± SD 13.1 ± 3.0 11.6 ± 4.0 12.9 ± 3.3 12.8 ± 2.7 7.3 ± 1.9 6.2 ± 3.6 Median 14.0 11.0 13.0 13.0 7.5 7.0 Range (8.0–18.0) (6.0–19.0) (9.0–19.0) (8.0–16.0) (4.0–10.0) (1.0–12.0) WOMAC pain subscale; mean ± SD 11.2 ± 3.6 7.1 ± 3.7 8.2 ± 3.9 11.1 ± 4.1 5.8 ± 2.8 4.0 ± 3.0 Median 10.0 7.0 8.0 10.5 4.5 3.0 Range (6.0–19.0) (1.0–12.0) (3.0–15.0) (7.0–19.0) (3.0–11.0) (0.0–8.0) WOMAC stiffness subscale; mean ± SD 3.9 ± 1.9 3.2 ± 2.0 3.7 ± 2.0 3.6 ± 2.6 2.4 ± 1.9 1.9 ± 1.7 Median 4.0 2.0 5.0 3.5 2.0 2.0 Range (0.0–7.0) (0.0–6.0) (0.0–6.0) (1.0–8.0) (0.0–6.0) (0.0–4.0) WOMAC disability subscale; mean ± SD 37.1 ± 15.6 26.3 ± 17.2 26.4 ± 14.7 41.0 ± 14.2 19.0 ± 12.6 15.2 ± 11.6 Median 43.0 22.0 26.0 37.0 20.5 21.0 Range (11.0–56.0) (2.0–58.0) (6.0–50.0) (27.0–68.0) (4.0–35.0) (0.0–33.0) Patient Likert score (cm); mean ± SD 1.1 ± 0.8 2.1 ± 1.1 2.1 ± 0.9 1.2 ± 0.6 2.8 ± 0.9 2.7 ± 0.7 Median 1.0 2.0 2.0 1.0 3.0 3.0 Range (0.0–2.0) (1.0–4.0) (1.0–3.0) (0.0–2.0) (1.0–4.0) (2.0–4.0) Physician Likert score (cm); mean ± SD 1.0 ± 0.8 2.3 ± 1.0 2.5 ± 0.9 1.5 ± 0.7 3.1 ± 0.4 3.1 ± 0.6 Median 1.0 2.0 2.5 2.0 3.0 3.0 Range (0.0–2.0) (1.0–4.0) (1.0–4.0) (0.0–2.0) (3.0–4.0) (2.0–4.0) Patient drug evaluation (cm); mean ± SD 2.4 ± 1.0 2.1 ± 0.8 2.9 ± 0.6 3.1 ± 0.6 Median 3.0 2.0 3.0 3.0 Range (1.0–4.0) (1.0–3.0) (2.0–4.0) (2.0–4.0) Physician drug evaluation (cm); mean ± SD 2.1 ± 1.4 2.3 ± 1.0 2.9 ± 0.4 3.1 ± 0.6 Median 2.0 2.5 3.0 3.0 Range (0.0–4.0) (0.0–3.0) (2.0–3.0) (2.0–4.0) Analgesic usage (tablets day−1 ); mean ± SD 40.4 ± 17.1 53.3 ± 20.0 71.1 ± 38.6 40.4 ± 17.1 13.0 ± 10.9 7.0 ± 4.9 Median 30.0 60.0 60.0 30.0 12.0 7.0 Range (16.0–60.0) (30.0–90.0) (30.0–150.0) (16.0–60.0) (0.0–30.0) (0.0–14.0)
